Trials / Completed
CompletedNCT00367757
STAR-AF:Substrate Versus Trigger Ablation for Reduction of Atrial Fibrillation Trial
Open, Prospective, Randomized Trial Comparing Trigger vs Substrate vs Hybrid Approaches for AF Ablation
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 107 (actual)
- Sponsor
- Abbott Medical Devices · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Patient Population: Patients with AF that is symptomatic and refractory to at least one antiarrhythmic medication. Patients must have AF that is paroxysmal (\>4 episodes within 6 months, two episodes \>6 hours within 1 year) or persistent (sustained episode \<6 months terminated by cardioversion or drug). Purpose: To compare a trigger-based technique (pulmonary vein isolation) to a substrate-based technique (high-frequency, fractionated EGMs) to a combined approach for AF ablation
Detailed description
Interventions: Patients will be randomized to either wide circumferential pulmonary vein isolation ("trigger") or ablation of high-frequency, fractionated electrograms during AF ("substrate"), or a hybrid approach combining trigger and substrate. Both techniques will be performed with NavX mapping system and a standardized ablation catheter. Endpoint of PVI will be isolation of all four PVs documented by circular catheter. Endpoint for substrate-based ablation will be termination and noninducibility of AF. Up to 2 procedures will be allowed within 6 months. A 2 month blanking period will be allowed after each procedure during which early recurrences will not be counted. Outcomes: * Recurrence of atrial fibrillation or other atrial tachycardia at 3, 6, and 12 months post-initial procedure. * Recurrence will be defined by symptoms and/or ECG/Holter data showing AF \> 2 mins * Occurrence of adverse events in each group post-procedure. * Quality of life assessment at 6 and 12 months post-initial procedure. Followup: * 3, 6, and 12 months post-initial procedure. * Clinical data, ECG, Holter, loop recorder at baseline and at each visit. * QOL at baseline, 3, 6 and 12 months post-initial procedure.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | Ablate AF triggers via PVI | Trigger-based ablation guided by pulmonary vein antrum isolation |
| PROCEDURE | Substrate via CFAEs | Substrate-based ablation using an approach targeting CFAEs |
| PROCEDURE | Combined approach for AF ablation | Combined trigger and substrate based approach |
Timeline
- Start date
- 2006-08-01
- Primary completion
- 2009-07-01
- Completion
- 2009-07-01
- First posted
- 2006-08-23
- Last updated
- 2019-01-30
Locations
8 sites across 4 countries: Canada, Italy, Norway, Spain
Source: ClinicalTrials.gov record NCT00367757. Inclusion in this directory is not an endorsement.